SEVERE ACUTE RESPIRATORY SYNDROME (SARS) TREATMENT MARKET ANALYSIS

Severe acute respiratory syndrome (SARS) is a viral respiratory illness that can be fatal and contagious. Both SARS and COVID-19 are caused by SARS-associated coronaviruses. SARS is caused by the virus SARS-CoV and COVID-19 is caused by virus SARS-CoV2. The infections SARS-CoV and COVID-19 occur in both animals and humans. 

According to Center for disease control and prevention (CDC) and World Health Organization (WHO), the first case of SARS was detected in South China in November 2002 and later in March 2003, SARS was then identified as a global hazard. As stated by Center for disease control and prevention (CDC), from November 2002 to July 2003, a total of 8,098 people became sick with severe acute respiratory syndrome in the world and 774 of them died. No new cases of SARS-CoV after July 2003 has been reported yet. The treatment of SARS-CoV is still evolving and no optimal cure is found so far.

However, the recent outbreak of COVID-19 disease created a havoc in the world and is still affecting millions of people worldwide. As mentioned by World health organization, it was first reported in Wuhan, China on December 31, 2019 and further, declared as a global pandemic by World Health Organization in March 2020.

The healthcare system is under strain as a result of alarming number of cases and deaths due to COVID-19, scientists and research institutes worldwide are racing against the clock to find a cure for COVID-19.

Global Severe Acute Respiratory Syndrome (SARS) Treatment Market – Dynamics

Rising cases of COVID-19 is expected to propel growth of the SARS treatment market across globe over the forecast period. As stated by the World Health Organization, over 170.8 million confirmed cases and 3.5 million deaths of coronavirus disease (COVID-19) were reported up till June 2, 2021 across the globe.

Increasing drug approvals for emergency use authorization (by regulatory authorities) for the treatment of COVID-19 has led to a dynamic surge in SARS treatment market. For instance, the Drug Controller General of India approved the drug known as 2-DG, which is a powdered form of the molecule 2-deoxy-D-glucose developed by the Institute of Nuclear Medicine and Allied Sciences (INMA), a leading laboratory of the Defense Research and Development Organization (DRDO) in collaboration with Dr. Reddy’s laboratories (DRL), for emergency use in May 2021. The results of the clinical trials demonstrated that 2-DG helps the moderate and severe COVID-19 patients to recover faster and also decreases the need of supplemental oxygen. Moreover, US Food drug and administration (FDA) approved GlaxoSmithKline developed medication known as Sotrovimab, for emergency use on June 1, 2021. Sotrovimab is a monoclonal antibody which would be used for treating mild to moderate COVID-19 patients.

In addition, scientists are still researching and experimenting for a valid cure against COVID-19, which leaves a scope for more new launches in future, thereby leading to a boost in the SARS treatment market. For instance, according to the U.S. Food and drugs administration (FDA) Coronavirus Treatment Acceleration Program (CTAP) dashboard, as of April 2021, more than 610 drug development programs are in planning stages and above 450 trials are being reviewed for the treatment of COVID-19.

Global Severe Acute Respiratory Syndrome (SARS) Treatment Market – Regional Insights

North America was found to dominate the market growth, owing to the number of drug approvals for the treatment of COVID-19 in hospitals. For instance, FDA approved Remdesivir in November 2020 manufactured by Gilead sciences, a biopharmaceutical company focused on manufacturing antiviral drugs, as the first treatment against COVID-19 disease.

Asia Pacific is expected to show lucrative growth during the forecast period, owing to increased production of drugs for COVID-19 treatment by market players in order to combat the pandemic. For instance in May 2020, almost 70 metric tons of Hydroxychloroquine was manufactured in India by Zydus Cadila, and Ipca laboratories, and exported to neighboring countries along with the U.S. Zydus Cadila and Ipca labs are international pharmaceutical companies that manufacture generic drugs and active pharmaceutical ingredients respectively.

Global Severe Acute Respiratory Syndrome (SARS) Treatment Market- Taxonomy

By Drug Class:

• Antibiotics
• Azithromycin
• Antivirals
• Ribavirin
• Lopinavir
• Ritonavir
• Remdesivir
• Corticosteroids
• Methylprednisolone
• Prednisolone
• Dexamethasone
• Monoclonal antibodies
• Sotrovimab
• Bamlanivimab and Etesevimab
• REGEN-COV (Casirivimab and Imdevimab)
• Baricitinib (Olumiant)
• Others

By Indication:

• SARS-CoV
• SARS-CoV2

By Route of Administration:

• Oral
• Intravenous

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Key players in the Global Severe Acute Respiratory Syndrome (SARS) Treatment Market:

Some of the key players operating in the Severe Acute Respiratory Syndrome (SARS) Treatment Market includes Gilead Sciences Inc., Hetero labs Ltd., Cipla Ltd., Cadila healthcare Ltd., Ipca laboratories, GlaxoSmithKline plc., Novartis, Pfizer Inc., Roche Holding AG, AbbVie, Takeda Ltd., Johnson & Johnson, Boehringer Ingelheim, Eli Lily & Co., and AstraZeneca plc.